Herpes simplex virus type 2 acquisition during recent HIV infection does not influence plasma HIV levels

被引:9
作者
Cachay, Edward R. [1 ]
Frost, Simon D. W. [1 ]
Poon, Art F. Y. [1 ]
Looney, David [1 ,2 ]
Rostami, Sherry M. [1 ]
Pacold, Mary E. [1 ]
Richman, Douglas D. [1 ,2 ]
Little, Susan J. [1 ]
Smith, Davey M. [1 ,2 ]
机构
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Vet Adm San Diego Healthcare Syst, San Diego, CA USA
关键词
HIV RNA; incident herpes simplex virus-2; viral dynamics;
D O I
10.1097/QAI.0b013e318163bd87
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We assessed the effect of herpes simplex virus type 2 (HSV-2) acquisition on the plasma HIV RNA and CD4 cell levels among individuals with primary HIV infection using a retrospective cohort analysis. We studied 119 adult, antiretroviral-naive, recently HIV-infected men with a negative HSV-2-specific enzyme immunoassay (EIA) result at enrollment. HSV-2 acquisition was determined by seroconversion on HSV-2 EIA, confirmed by Western blot analysis. Ten men acquired HSV-2 infection a median of 1.3 years after HIV infection (HSV-2 incidence rate of 7.4 per 100 person-years of follow-up). The median time of follow-up after acquiring HSV-2 infection was 303 days. All men except I were asymptomatic during HSV-2 acquisition, and only I HSV-2 seroconverter, who was asymptomatic, had a transient increase in blood HIV load (0.5 log(10) copies/mL over 11 days). The HSV-2 incidence rate was high in our cohort of recently HIV-infected individuals; however, HSV-2 acquisition did not significantly change the plasma HIV dynamics and CD4 cell levels.
引用
收藏
页码:592 / 596
页数:5
相关论文
共 14 条
[1]   Time course of Seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2 [J].
Ashley-Morrow, R ;
Krantz, E ;
Wald, A .
SEXUALLY TRANSMITTED DISEASES, 2003, 30 (04) :310-314
[2]   Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection [J].
Cachay, Edward R. ;
Frost, Simon D. W. ;
Richman, Douglas D. ;
Smith, Davey M. ;
Little, Susan J. .
JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (09) :1270-1277
[3]   Innate immunity to herpes simplex virus type 2 [J].
Duerst, RJ ;
Morrison, LA .
VIRAL IMMUNOLOGY, 2003, 16 (04) :475-490
[4]   Protective vaccination against genital herpes simplex virus type 2 (HSV-2) infection in mice is associated with a rapid induction of local IFN-γ-dependent RANTES production following a vaginal viral challenge [J].
Harandi, AM ;
Svennerholm, B ;
Holmgren, J ;
Eriksson, K .
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2001, 46 (06) :420-424
[5]   Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers [J].
McFarland, W ;
Gwanzura, L ;
Bassett, MT ;
Machekano, R ;
Latif, AS ;
Ley, C ;
Parsonnet, J ;
Burke, RL ;
Katzenstein, D .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (05) :1459-1465
[6]   The impact of active herpes simplex virus infection on human immunodeficiency virus load [J].
Mole, L ;
Ripich, S ;
Margolis, D ;
Holodniy, M .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (03) :766-770
[7]   Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus [J].
Nagot, Nicolas ;
Ouedraogo, Abdoulaye ;
Foulongne, Vincent ;
Konate, Issouf ;
Weiss, Helen A. ;
Vergne, Laurence ;
Defer, Marie-Christine ;
Djagbare, Didier ;
Sanon, Anselme ;
Andonaba, Jean-Baptiste ;
Becquart, Pierre ;
Segondy, Michel ;
Vallo, Roselyne ;
Sawadogo, Adrien ;
Van de Perre, Philippe ;
Mayaud, Philippe ;
Bahembera, E. ;
Berthe, A. ;
Coulibaly, M. ;
Defer, M. -C. ;
Diallo, R. ;
Djagbare, D. ;
Konate, I. ;
Ky-Dama, F. ;
M'Boutiki, G. T. ;
Meda, N. ;
Millogo, I. ;
Nagot, N. ;
Ouedraogo, A. ;
Ouedraogo, D. ;
Rouet, F. ;
Sanon, A. ;
Sawadogo, H. ;
Vallo, R. ;
Vergne, L. ;
Mayaud, P. ;
Nagot, N. ;
Weiss, H. A. ;
Becquart, P. ;
Foulongne, V. ;
Segondy, M. ;
Van de Perre, P. ;
Andonaba, J. -B. ;
Sawadogo, A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :790-799
[8]  
*R DEV COR TEAM, 2007, R LANG ENV STAT COMP
[9]   Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and seroincidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons [J].
Ramaswamy, M ;
Sabin, C ;
McDonald, C ;
Smith, M ;
Taylor, C ;
Geretti, AM .
SEXUALLY TRANSMITTED DISEASES, 2006, 33 (02) :96-101
[10]   HSV shedding [J].
Sacks, SL ;
Griffiths, PD ;
Corey, L ;
Cohen, C ;
Cunningham, A ;
Dusheiko, GM ;
Self, S ;
Spruance, S ;
Stanberry, LR ;
Wald, A ;
Whitley, RJ .
ANTIVIRAL RESEARCH, 2004, 63 :S19-S26